2025 annual financial data
Spero Therapeutics 2025 Operating cash flow margin
Direct answer
Operating cash flow margin was -21.17%.
Operating income was -24,000 USD and net income was 8,572,000 USD.
Operating cash flow was -12,624,000 USD.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 59,619,000 USD
- Operating income
- -24,000 USD
- Net income
- 8,572,000 USD
- Operating cash flow
- -12,624,000 USD